Dendreon to Hold Conference Call on Thursday, May 10, 2007 at 4:30 PM ET
Posted on: Wednesday, 9 May 2007, 21:00 CDT
SEATTLE, May 9 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced the Company will hold a conference call tomorrow Thursday, May 10, 2007 to discuss its first quarter 2007 financial results, as well as the complete response letter it received from the U.S. Food and Drug Administration for Provenge(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy under review for the treatment of asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.
Time: 4:30 PM ET /1:30 PM PT Date: May 10, 2007 Dial-in: 1-866-293-8972 (domestic) or +1-913-312-1232 (international) Webcast: http://www.dendreon.com/ (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 3324857. The replay will be available from 2:00 pm ET on Thursday, May 10 until 11:59 pm ET on Monday, May 14. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com/.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
Dendreon Corporation
CONTACT: Monique Greer, Sr. Director, Corporate Communications ofDendreon Corporation, +1-206-829-1500
Web site: http://www.dendreon.com/
Source: PRNewswire-FirstCall
Related Articles
- Dendreon Reports Third Quarter 2007 Financial Results
- -Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET-
- Dendreon Reports Positive Results for Breast Cancer Treatment
- Dendreon to Hold Conference Call on Second Quarter 2007 Financial Results
- Centene Corporation to Present at Bank of America Health Care Conference 2007
- Dendreon Reports First Quarter 2007 Financial Results
- Noble Corporation to Present at the Calyon Energy Conference 2007
- Energy Conversion Devices to Hold Corporate-Update Conference Call for Investors and Analysts on Thursday, April 19, 2007
- Dendreon's APC8024 Immunotherapy Shows Promise in Advanced Breast Cancer
 |
 |
User Comments (0)
RSS Feeds